Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NVO Weight-Loss Drug Gets Positive Data
09:14am, Friday, 24'th Jan 2025
Novo Nordisk (NVO) pops on positive drug trial results. The company showed a 22% reduction in weight for obese and overweight patients after 36 weeks.
Ozempic maker's stock surges. A trial of a new Novo Nordisk drug shows promise.
08:47am, Friday, 24'th Jan 2025
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible v
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
06:51am, Friday, 24'th Jan 2025
On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
06:05am, Friday, 24'th Jan 2025
The Danish drugmaker announced new data for its new weight-loss drug Amycretin Friday.
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
06:02am, Friday, 24'th Jan 2025
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
05:39am, Friday, 24'th Jan 2025
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous administration, saying people with obesity or overweight treated with the drug achieved a 22%
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
05:19am, Friday, 24'th Jan 2025
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for onc
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Thursday, 23'rd Jan 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about Securities Fraud Investigation - NVO
07:25am, Thursday, 23'rd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible v
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
05:47am, Thursday, 23'rd Jan 2025
Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how analysts view a given stock.
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
06:51pm, Wednesday, 22'nd Jan 2025
In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
09:55am, Wednesday, 22'nd Jan 2025
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategi
Novo Nordisk A/S Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - NVO
07:25am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible v
